FindMyKOL

Lamont Weide, MD, PhD, FACE

Basic profile

University of Missouri–Kansas City

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionKansas City, MO · MidwestSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLFindMyKOL type: RegionalLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Lamont Weide is an Endocrinology/Metabolic physician affiliated with University of Missouri–Kansas City. OpenAlex indexes 48 publications with 1,468 citations (h-index 15).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
48publications

Publications indexed by OpenAlex. Counts exclude supporting files.

1,468citations

Citations across these publications.

15h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
6companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • PFIZER INC.
    Program year20251 payment
    $15
  • Lilly USA, LLC
    Program year20234 payments
    $70
  • ANI Pharmaceuticals, Inc.
    Program year20231 payment
    $32
All 8 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    41.9%
    Statin14.8%
    Atorvastatin Calcium74%Rosuvastatin Calcium17%Pravastatin Sodium7%Lovastatin2%
    Part D<11 patients
    Calcium channel blocker5.6%
    Amlodipine Besylate94%Nifedipine Er6%
    Part D<11 patients

    + 12 more classes in this area

  • Metabolism & gastrointestinal

    39.9%
    GLP-1 receptor agonist11.1%
    Trulicity47%Ozempic40%Victoza 3-Pak6%Rybelsus4%Victoza 2-Pak3%
    Part D<11 patients
    Insulin Analog11.1%
    Lantus Solostar36%Novolog Flexpen21%Humalog Kwikpen U-10011%Novolog7%Insulin Lispro Kwikpen U-1007%Tresiba Flextouch U-1006%Basaglar Kwikpen U-1006%Tresiba Flextouch U-2003%Humalog3%
    Part D<11 patients

    + 8 more classes in this area

  • Hormonal (systemic)

    14.7%
    l-Thyroxine12.9%
    Levothyroxine Sodium87%Synthroid13%
    Part D≥112 patients
    Thyroid Hormone Synthesis Inhibitor1.5%
    Methimazole100%
    Part D≥14 patients

    + 1 more class in this area

Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

All 48 publications: search, sort and filter.Explore →

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”